How Technology is Revealing the Big Picture in Pharma

July 24, 2018

The collection and analysis of data generated outside of restricted clinical trials are now critical to pharma companies. Data gathered in the routine delivery of healthcare can be mined to uncover insights into treatment efficacies and outcomes in the real world. Such insights, known as real-world evidence (RWE), benefits teams working across the drug lifecycle by showing how larger, heterogeneous patient populations interact with the healthcare system and respond to medicines.

Spotlight

TeselaGen Biotechnology

TeselaGen's artificial Intelligence powered platform radically accelerates product development of therapeutics, high value chemicals, and agricultural products. We are located in San Francisco.

OTHER WHITEPAPERS
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
news image

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More
news image

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More

Spotlight

TeselaGen Biotechnology

TeselaGen's artificial Intelligence powered platform radically accelerates product development of therapeutics, high value chemicals, and agricultural products. We are located in San Francisco.

Events